The p21‐activated kinase 1 (Pak1) signalling pathway in cardiac disease: from mechanistic study to therapeutic exploration
British Journal of Pharmacology2017Vol. 175(8), pp. 1362–1374
Citations Over TimeTop 10% of 2017 papers
Abstract
This article is part of a themed section on Spotlight on Small Molecules in Cardiovascular Diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.8/issuetoc.
Related Papers
- → LAT-Independent Erk Activation via Bam32-PLC-γ1-Pak1 Complexes: GTPase-Independent Pak1 Activation(2012)34 cited
- → Evidence for a Novel Mechanism of the PAK1 Interaction with the Rho-GTPases Cdc42 and Rac(2013)25 cited
- → Analysis of Small GTPase Signaling Pathways Using p21-activated Kinase Mutants That Selectively Couple to Cdc42(2001)32 cited
- → Targeting PAK1 with the Small Molecule Drug AK963/40708899 Suppresses Gastric Cancer Cell Proliferation and Invasion by Downregulation of PAK1 Activity and PAK1‐Related Signaling Pathways(2019)10 cited
- → Development and utility of a PAK1-selective degrader(2022)2 cited